Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QQGU | ISIN: CA4236943060 | Ticker-Symbol: 2VF0
Stuttgart
27.06.25 | 08:00
0,079 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
HEMOSTEMIX INC Chart 1 Jahr
5-Tage-Chart
HEMOSTEMIX INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0680,09627.06.
0,0760,08727.06.

Aktuelle News zur HEMOSTEMIX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrHemostemix Inc.: Croom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health Launch214Calgary, Alberta--(Newsfile Corp. - June 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III autologous stem cell therapy company and Mr. Croom Lawrence are pleased to announce...
► Artikel lesen
FrHemostemix Inc (2): Hemostemix chairman Lacey subscribes for $1.5M in units4
DoHemostemix Inc.: Hemostemix Announces Lead Order of $1,500,000 and the Full Repayment of $2,500,000 Convertible Debenture112Calgary, Alberta--(Newsfile Corp. - June 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces its Chairman, Peter Lacey, has provided the Company...
► Artikel lesen
18.06.Hemostemix Inc (2): Hemostemix closes $469,366 private placement2
17.06.Hemostemix Inc.: Hemostemix Closes Private Placement of $469,366269Calgary, Alberta--(Newsfile Corp. - June 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces the closing of a non brokered private placement...
► Artikel lesen
30.05.Hemostemix Inc (2): Hemostemix 1,634,466-share private placement3
20.05.Hemostemix Inc.: Hemostemix Presents at TERMIS 2025, Freiburg, Germany166Freiburg, Germany--(Newsfile Corp. - May 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III clinical-stage biotechnology company developing autologous stem cell therapies for...
► Artikel lesen
HEMOSTEMIX Aktie jetzt für 0€ handeln
13.05.Hemostemix Inc (2): Hemostemix closes $336,500 (U.S.) financing2
12.05.Hemostemix Inc.: Hemostemix Closes Private Placement of USD $336,500 at $0.295 per Share209Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), per the Company's February 4, 2025 news release, closed the...
► Artikel lesen
08.05.Hemostemix Inc.: Hemostemix at Invest Stuttgart283Calgary, Alberta--(Newsfile Corp. - May 8, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is poised to make a significant impact at Invest Stuttgart...
► Artikel lesen
23.04.Hemostemix Inc (2): Hemostemix to get patent expertise with partnership3
23.04.Hemostemix Inc.: Hemostemix Engages PatentVest to Strengthen its Global Patent Portfolio297Calgary, Alberta--(Newsfile Corp. - April 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) a leader in the development of autologous stem cell therapy for the treatment of cardiovascular...
► Artikel lesen
17.03.Hemostemix Inc (2): Hemostemix talks up vascular dementia treatment ACP-013
17.03.Hemostemix Inc.: Hemostemix's Pitch to Wall Street: ACP-01 Vascular Dementia Trial will Generate $5,365,000, Capture Data, as a Phase 1 Clinical Trial614Calgary, Alberta--(Newsfile Corp. - March 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated...
► Artikel lesen
06.03.Hemostemix Inc (2): Hemostemix, Firefly to study brain wave activity5
06.03.Hemostemix Inc.: Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01361Calgary, Alberta--(Newsfile Corp. - March 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated...
► Artikel lesen
05.03.Hemostemix Inc (2): Hemostemix sells 15 ACP-01 convertible debentures3
05.03.Hemostemix Inc.: Hemostemix Sells Its 23rd ACP-01 Therapy Convertible Debenture313Calgary, Alberta--(Newsfile Corp. - March 5, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell therapy company that has safely...
► Artikel lesen
20.02.Hemostemix Inc (2): Hemostemix to license CytoImmune's Bioreactor tech10
19.02.Hemostemix Inc.: Hemostemix Licenses CytoImmune's BioReactor Technologies389Calgary, Alberta--(Newsfile Corp. - February 19, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce a strategic breakthrough that...
► Artikel lesen
Weiter >>
62 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1